The November storm clouds may have parted above the Jefferies Global Healthcare Conference in London last week, but market ...

Bayer’s oral FXIa inhibitor asundexian has significantly reduced the risk of stroke in a phase 3 trial, giving a boost to a potentially blockbuster mechanism that has suffered setbacks over the past ...

The CDC is instructing scientists to end all research involving monkeys by the end of the year, in a move that will ...

The FDA says it is hiring more than 1,000 new employees and rolling out a pilot communication program in efforts to speed up ...

Johnson & Johnson is paying $3.05 billion to acquire Halda Therapeutics, obtaining a novel cell death platform while ...

Roche has claimed the exclusive international rights to Freenome’s multiomic cancer screening approaches, toward the goal of ...

The survey was disseminated among biopharma CEOs and regulatory affairs leaders and focused on recent experiences with the ...

Nurix Therapeutics is trimming its workforce not long after launching a pivotal phase 2 trial for its lead cancer asset. | ...

With much of Moderna’s recent rise tied to its COVID-19 vaccine, the company has struggled to match the sales highs it ...

GE HealthCare plans to pay $2.3 billion in cash to acquire imaging software developer Intelerad, toward the goal of building ...

The Fierce team will be out of office next Friday for the Thanksgiving holiday. The next edition of Chutes & Ladders will ...

In January, Exact Sciences CEO Kevin Conroy told us that 2025 was shaping up to be a transformative year for the diagnostics ...